Future Fields

See anyone you recognize? 👀 We're fly by design, but powered by people. Our #FutureFielders are the ones working on your custom protein expression strategies, manufacturing in the cleanrooms, and keeping our flies fed 365 days a year. View our team on our updated site 👉 https://bit.ly/41nQAU5

📢 We're #HIRING! We’re looking for a detail-oriented QC Technician to ensure our products are as impactful as the mission behind them. View job posting and apply 👉 https://bit.ly/4saEGsA Know someone who would be a fit? Send them this post! 💌 #yegjobs #yegbio #biotech

📢 We're HIRING! We're looking for a pragmatic, tech savvy QC Lead to power our industry-leading manufacturing engine. View job posting and apply 👉 https://bit.ly/4sGU000 Know someone who would be a fit? Send them this post! 💌 #hiring #yegjobs #yegbio #biotech

“Interleukins produced today are identical to those produced years later” This snapshot from our latest Interleukins Whitepaper highlights reproducible, scalable and TSE/BSE risk-free production of cytokines. With EntoEngine™, CGT teams no longer have to choose between quality and scalability in their ancillary material supply. Download the whitepaper to explore the data https://bit.ly/3MYs1te #Biotech #CellTherapy #ScaleUp #EntoEngine

See you soon, San Francisco! We're heading to World Agri-Tech 2026 🌾 Reach out to @Joshua Geilhufe via the 1:1 booking platform or LinkedIn to learn more about how whole fruit flies can be leveraged to make your intractable proteins. 🪰

Is your cytokine supply the silent killer of your scale-up strategy? In Cell & Gene Therapy (CGT) ancillary material manufacturing, traditional protein expression systems aren't keeping pace with stringent quality and rapid scalability needs. EntoEngine™ was built to overcome those limitations, delivering recombinant cytokines that combine biological authenticity, batch consistency, and regulatory readiness. In our new whitepaper, we share performance data from the expression of IL-2, IL-10, and IL-12, highlighting: 📊 Lot-to-Lot Consistency: bioactivity across lots 🔬 Functional Stability: long-term biological activity. 🛡️ Regulatory De-risking: eliminating adventitious agent concerns. 🏭 Scalability on Demand: flexible production aligned with milestones. Download our latest whitepaper to access the data and engineering strategies here: https://lnkd.in/gWWnZGdK #CellandGeneTherapy #FutureFields #Cytokines #Interleukins #AncillaryMaterials #CGT

Future Fields dot io received a facelift 😍 What's new on the site: 🪰 Updated FAQ on the Technology page: https://bit.ly/4tzrBKr 💼 Case studies all in one location on the Services page: https://bit.ly/462QNil ✨ New visuals highlighting our novel expression system Check it out 👉 https://bit.ly/409AcWA

Fresh off the heels of #PepTalk2026, we’re excited to share a new feature article from Peptide and Protein News, highlighting protein expression in transgenic Drosophila melanogaster (yes, whole fruit flies). Inside this 3-5 minute read, you can find: 🪰 How the #EntoEngine leverages transgenic fruit flies as "living bioreactors" 📑 A breakdown of case study results 🏭 Insight into our scale-up manufacturing 💰 Cost comparison with traditional systems Check it out here: https://bit.ly/49ZQyHf Have questions? Drop a comment below 👇

Congratulations Muthukumaran Venkatachalapathy, PhD for winning our Arcteryx backpack prize draw! 🎒🥳 All the best in your journey in #drugdiscovery research at Yale University. 🙌